OBSV News and Press, ObsEva SA From 06/30/21

-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfer - GENEVA, Switzerland and BOSTON – June 30 , 202...

- Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation ; Top-line data from pilot study of Yselty for the treatment of severe adenomyosis to be presented in an ePost ...

ObsEva (OBSV) presents clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for the treatment of spontaneous preterm labor at the RCOG Virtual World Congress 2021.As previously disclosed in November 2020, the PROLONG data demonstrated that ebopiprant was ...

- PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation - - Phase 2b /3 adaptive dose - ranging study planned to initiate in Q4:21- GENEVA, Switzerland and BOSTON, MA –...

- D ata from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous p reterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA – June 2 , 202...

Geneva, Switzerland and Boston, MA – May 31 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced...

Geneva, Switzerland and Boston, MA – May 25 , 202 1 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced th...

ObsEva (OBSV) perks up 7% premarket after announcing final 76-week results from the PRIMROSE 1 study of Yselty (linzagolix), in development for the treatment of women with heavy menstrual bleeding due to uterine fibroids.These results mark the final data measuring point for both the Phas...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips ObsEva  (NASDAQ: OBSV ) stock is on the move this morning after the Swiss biopharma reported positive results from trials of its Yselty treatment for uterine fibroids. OBSV stock was up 5.65% in pre-market trading...

Virgin Galactic Holdings (SPCE) +21% after test flight scheduled for May 22VistaGen Therapeutics (VTGN) +15% after Baird calls stock 'significantly undervalued'.Allogene Therapeutics (ALLO) +13% on positive early-stage data for CAR T candidates in blood cancer.PDS Biotechnology...